Metastatic Breast Cancer With Liver Progression Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 3+, Ki67 15%. Liver metastasis: ER 30%

Metastatic Site: pleura, liver

After several periods of response and later liver progression, she remained on active treatment with pegylated liposomal doxorubicin.

PubMed CentralRead more →

Recurrent Breast Cancer With Liver Metastases Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: Initial tumor: ER positive, HER2 0. Liver metastasis: ER 100%

Metastatic Site: liver

After liver progression following 18 cycles of eribulin, she started weekly carboplatin and remained in active treatment.

PubMed CentralRead more →

Metastatic Breast Cancer With Brain, Bone, Lung and Liver Disease Responding During Eribulin Treatment

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 negative, Ki67 10%. Lung metastasis: ER 90%

Metastatic Site: lung, bone, brain, liver

Eribulin remained ongoing with reduced brain lesions, stable bone disease and continued shrinkage of liver metastases after prior systemic progression.

PubMed CentralRead more →

Stage III HER2-Positive Invasive Ductal Carcinoma: Dorothy's Survivor Story

Patient Info: Dorothy Paterson, Female, 40s | Stage III

Biomarkers: HER2-positive

As of November 2016, Dorothy had remained cancer-free since completing treatment for Stage III HER2-positive invasive ductal carcinoma in April 1999.

MD AndersonRead more →

Stage III Inflammatory Breast Cancer Diagnosed After Severe Breast Pain and Swelling Following Mammography

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER negative, PR negative, HER2 highly positive

After later metastatic disease was found, she chose no further active treatment and died of progressive disease in 2012.

PubMed CentralRead more →

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed CentralRead more →

BRCA1-associated right invasive ductal carcinoma followed by left acinic cell carcinoma of the breast

Patient Info: Anonymized, Female, 40s

Biomarkers: Constitutional BRCA1 mutation. Right breast cancer was ER/PR positive, HER2 negative; later left tumor was triple-negative with TP53 change.

After treatment for right invasive ductal carcinoma and later contralateral acinic cell carcinoma, she was alive and well 19 months after the acinic cell carcinoma surgery, with no evidence of disease while continuing hormonal therapy.

PubMed CentralRead more →

Metastatic lobular breast cancer to gynecologic sites: disease-free after surgery and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2/C-Erb-B2-negative

Metastatic Site: vagina, uterus, ovaries

After treatment of vaginal, uterine, and ovarian metastases from lobular breast cancer, she was free from disease 12 months after completion surgery.

PubMed CentralRead more →

Hormone-positive breast cancer with axillary recurrence responding to hyperthermia, radiation, and chemotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative

The left axillary recurrence enlarged during weekly paclitaxel and radiotherapy, then became nearly flat and was assessed as a complete response 8 weeks after adding hyperthermia.

PubMed CentralRead more →

ER-positive breast cancer recurrence after DCIS: chemotherapy, nodal surgery, radiation, and endocrine therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Recurrent invasive breast cancer: ER-positive; HER2/neu-negative. PR not reported.

Disease-free for 33 months after treatment of ER-positive, HER2-negative invasive breast cancer recurring in the mastectomy skin flap with positive axillary sentinel nodes.

PubMed CentralRead more →